The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:
Pharma Mar phase III trial with Zepsyre in small-cell lung cancer patients to continue without changes on positive recommendation by IDMC (independent data monitoring committee).
Tubos Reunidos on Wednesday reported a 9-month net loss of 17.5 million euros after a loss of 25.8 million euros a year earlier.
ING cuts to “hold” from “buy” whlie raising the target price to 18.5 euros from 18.1 euros.
Duro felguera said on Tuesday 9-month net loss 11.5 million euros versus profit 1.6 million euros year ago.
Hispania 9-month net profit 179.2 million euros versus 136.7 million euros year ago.
Natra 9-month Ebitda 14.7 million euros, down 19 percent from year earlier.
For today’s European market outlook double click on.
For real-time moves on the Spanish blue-chip index IBEX please double click on
For IBEX constituent stocks highlight .IBEX in the command box and press the F3 button on your keyboard
For latest news on Spanish stock moves double click
For Spanish language market report double click on
For latest Eurostocks report please double click on